Insulin Pump Therapy for Type 2 Diabetes in 2026: Who Should Consider It, How It Works, and What the Evidence Shows
Once reserved almost exclusively for type 1 diabetes, continuous subcutaneous insulin infusion (CSII) via an insulin pum...
Once reserved almost exclusively for type 1 diabetes, continuous subcutaneous insulin infusion (CSII) via an insulin pum...
Long-acting insulin therapy remains a foundational tool for achieving glycemic control. This guide covers initiation, ti...
More than 30% of adults with type 2 diabetes eventually require basal insulin to achieve glycemic targets. Here is a cli...
From smart pens to proper injection technique, storage, and safety — a clinically detailed look at modern injectable dia...
Victoza — the once-daily GLP-1 receptor agonist — has transformed type 2 diabetes management. This comprehensive guide c...
Trulicity (dulaglutide) is a once-weekly GLP-1 receptor agonist approved for type 2 diabetes management. This evidence-b...
Empagliflozin has reshaped type 2 diabetes management. Here is the complete clinical breakdown — from HbA1c reduction an...
Once reserved as third-line agents, GLP-1 receptor agonists are now central to type 2 diabetes management. This in-depth...
Type 2 diabetes often develops without obvious symptoms. Learn to recognize the quiet, early warning signals that can he...
Recognizing the subtle and urgent signs of type 1 and type 2 diabetes in children can prevent life-threatening complicat...
Early detection remains the single most powerful tool against the type 2 diabetes epidemic. In 2026, the American Diabet...
The fasting blood sugar test is often the first — and most accessible — tool clinicians use to screen for diabetes. But ...